This protocol addresses chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) specifically in male patients who also present with urinary voiding symptoms — a defined clinical subpopulation for which guideline evidence supports a targeted first-line approach.
Male patients with CP/CPPS who experience concurrent urinary voiding symptoms represent a distinct presentation. Guideline recommendations specifically address this combination, and the evidence base for this subgroup is well-established.
The protocol targets measurable improvement across all NIH-CPSI domains: overall total score, urinary symptoms subscore, pain subscore, and quality-of-life subscore.
DOI: 10.1097/JU.0000000000004564
In patients with CP/CPPS and voiding symptoms, clinicians should offer treatment with an alpha-blocker.
Alpha-blockers were also associated with improvement versus placebo on each NIH-CPSI subscores (pain: 13 trials; n=1,243; urinary symptoms: 13 trials; n=1,243; and QOL: 13 trials; n=1,243).
View source ↗